Shares of Dr Reddy's Laboratories led the market losers after facing immense selling pressure this week. The pharmaceutical major fell over 9 percent over five trading sessions following corporate triggers regarding semaglutide supply disruptions. The sudden operational headwinds dragged down the otherwise positive momentum across large-cap healthcare equities.